Ovarian Cancer
Ovarian cancer is often diagnosed late because early symptoms can be subtle. Prompt specialist evaluation and personalized treatment planning are critical.
Updated on —
Understanding Ovarian Cancer: Symptoms, Diagnosis, Treatment, and Living Beyond It
Ovarian cancer is a serious illness, but it is not one single disease and it does not look the same in every person. This guide explains what ovarian cancer is, the symptoms people often notice, how doctors diagnose it, which treatments are commonly used, and what patients and families can do after diagnosis. The goal is to give you clear, trustworthy information in plain language so you can ask better questions and make informed decisions with your care team.
What is Ovarian Cancer?
Ovarian cancer is a cancer that begins in or closely around the ovaries, fallopian tubes, or the lining of the abdomen called the peritoneum. These cancers are often grouped together because they can behave in similar ways and are commonly treated with similar plans (NCI, 2025).
Cancer develops when cells in this area collect DNA changes that let them grow when they should not. Most ovarian cancers in adults are epithelial cancers. The most common subtype is high grade serous carcinoma. Many of these cancers may actually begin in the fallopian tube and then spread early into the abdomen, which helps explain why the disease is often found later (NCI, 2025).
Doctors usually stage ovarian cancer using the FIGO system. In simple terms, stage I is limited to the ovaries or fallopian tubes, stage II has spread within the pelvis, stage III usually involves the abdominal lining or nearby lymph nodes, and stage IV means spread outside the abdomen (NCI, 2025).
How common is Ovarian Cancer?
Ovarian cancer is less common than breast, lung, or colorectal cancer, but it remains one of the most serious gynecologic cancers because many cases are diagnosed after the disease has already spread. GLOBOCAN 2022 estimated about 324,603 new ovarian cancer cases and 206,956 deaths worldwide, showing the large global burden of this disease (IARC, 2024).
Risk rises with age, and many cases occur after menopause, although ovarian cancer can also affect younger people depending on the subtype. Germ cell tumors are more often seen in younger patients, while epithelial ovarian cancer is more common in older adults (NCI, 2025).
One reason ovarian cancer causes so much worry is that the symptoms can resemble bowel, bladder, or routine gynecologic problems. That overlap can delay diagnosis, especially when symptoms are dismissed as minor or temporary.
What causes Ovarian Cancer?
There is no single cause of ovarian cancer. In most people, it happens because of a mix of age, inherited risk, hormonal and reproductive factors, and chance DNA changes that build up over time. Some risk factors are strong, while others only slightly change risk and do not mean a person will definitely develop cancer (NCI, 2025).
The strongest inherited risk factors are harmful variants in BRCA1 or BRCA2. The National Cancer Institute reports that lifetime ovarian cancer risk is about 39 percent to 58 percent for women with a harmful BRCA1 variant and about 13 percent to 29 percent for women with a harmful BRCA2 variant, compared with about 1.1 percent in the general population (NCI, 2024).
Family history matters even without a known BRCA result. Having a mother, sister, or daughter with ovarian cancer increases risk. Lynch syndrome also raises risk and should be considered when there is a family history of ovarian, colon, or endometrial cancer. Other factors linked with higher risk include increasing age, endometriosis, postmenopausal hormone therapy, and obesity (NCI, 2025).
Many people ask what they did wrong. Usually, the honest answer is nothing. Most patients did not cause their cancer. What matters now is whether genetic testing, family history review, and specialist input could affect treatment choices for you and risk assessment for relatives.
What are the symptoms of Ovarian Cancer?
The most common symptoms of ovarian cancer are persistent bloating, pelvic or abdominal pain, feeling full quickly, trouble eating, and urinary urgency or frequency. These symptoms are common in many non cancer conditions too, so the key warning sign is that they are new, frequent, persistent, or clearly getting worse over time (American Cancer Society, 2025; NICE, 2025).
Symptoms often feel vague at first. People may notice that clothes fit tighter, meals seem harder to finish, or the lower abdomen feels heavy or uncomfortable. Some symptoms overlap with irritable bowel syndrome, urinary infections, menopause, or stress.
Common symptoms include:
Persistent bloating or abdominal swelling
Pelvic pain or abdominal pain
Feeling full quickly
Loss of appetite
Urinary urgency or frequent urination
Change in bowel habit
Unexplained fatigue
Unexplained weight loss, or weight gain from fluid build up
NICE advises testing when symptoms are persistent or frequent, especially more than 12 times in a month, and not simply written off as routine aging or digestive upset in someone over 50 (NICE, 2025).
How is Ovarian Cancer diagnosed?
Ovarian cancer is diagnosed through a combination of medical history, examination, imaging, blood tests, and tissue confirmation. Ultrasound and CA125 can help raise or lower suspicion, but they do not diagnose cancer on their own. A biopsy or tissue sample, plus scans to see how far the disease has spread, is usually needed to confirm the diagnosis and plan treatment (NCI, 2025; NICE, 2025).
In primary care, NICE recommends serum CA125 for women with suspicious symptoms, followed by abdominal and pelvic ultrasound if CA125 is 35 IU/ml or higher (NICE, 2025).
CA125 is useful, but it has limits. It can be high in ovarian cancer, yet it can also rise in non cancer conditions such as endometriosis, liver disease, pregnancy, and other inflammatory states. Some ovarian cancers do not produce a high CA125, especially early in the disease. That is why CA125 is one clue, not the whole answer (NCI, 2025).
Doctors may use:
Pelvic examination
Transvaginal or pelvic ultrasound
CT scan of the abdomen and pelvis
Sometimes MRI or PET in selected situations
Blood tests including CA125
Biopsy, cytology, or tissue obtained at surgery
It is also important to know what ovarian cancer diagnosis is not. There is no routine screening test for average risk women that has clearly been shown to reduce deaths from ovarian cancer. CA125 and ultrasound have been studied for screening, but they are not accurate enough for broad population screening because they can miss cancers and can also trigger false alarms (NCI, 2025).
Once doctors confirm the diagnosis, pathology identifies the subtype, grade, and molecular features such as BRCA mutation status or homologous recombination deficiency. These details now matter because they can influence the use of maintenance targeted therapy after initial treatment (Baradacs et al., 2024).
How is Ovarian Cancer treated?
Treatment for ovarian cancer usually includes surgery and chemotherapy, with targeted medicines added in selected cases. The exact plan depends on the subtype, stage, whether all visible disease can be removed, genetic findings, prior treatment history, and the person's overall health and goals of care (NCI, 2025; NICE, 2025).
The goal of treatment may be cure, long term control, or symptom relief. For some people with early stage disease, treatment aims to remove all cancer and lower the chance of it returning. For others with advanced or recurrent disease, treatment may focus on shrinking cancer, easing symptoms, and extending life while protecting quality of life.
Surgery
Surgery is often the most important first step, either before chemotherapy or after a few cycles of chemotherapy if doctors believe that approach gives the best chance of removing all visible disease. The aim is complete cytoreduction, meaning no visible cancer left behind when safely possible (NCI, 2025; NICE, 2025).
Depending on the stage and location, surgery may include removing the ovaries, fallopian tubes, uterus, omentum, and visible tumor deposits. Recovery can take time. Common issues after surgery include pain, constipation, fatigue, appetite loss, and emotional shock after a major diagnosis.
Chemotherapy
Chemotherapy is a core treatment for most epithelial ovarian cancers. A platinum drug, usually carboplatin, is commonly paired with paclitaxel. This may be given after surgery or before interval surgery when the disease is extensive or immediate surgery is not the best first step (NCI, 2025; NICE, 2025).
Side effects vary, but patients often worry most about nausea, hair loss, tiredness, low blood counts, infection risk, numbness or tingling in the hands and feet, constipation, and changes in taste. Supportive medicines can help many of these problems.
Radiation therapy
Radiation therapy is not the main treatment for most ovarian cancers, but it can be useful in selected situations. It may be used to ease pain, control bleeding, or treat a specific area causing symptoms. In that setting, the goal is usually symptom relief rather than treating disease throughout the abdomen (NCI, 2025).
Targeted therapy, antibody drug conjugates, and immunotherapy
Targeted therapy has changed ovarian cancer care, especially after a good response to first line platinum chemotherapy. PARP inhibitors such as olaparib, niraparib, and rucaparib are used in selected settings, particularly for BRCA mutated cancers and some cancers with homologous recombination deficiency. A 2024 systematic review and meta analysis found that PARP inhibitors are effective in newly diagnosed and recurrent ovarian cancer and are generally well tolerated, although serious adverse effects can occur in some patients (Baradacs et al., 2024).
Bevacizumab may also be used in some advanced cases depending on the treatment plan and local practice. A newer option in some recurrent platinum resistant cases is mirvetuximab soravtansine for folate receptor alpha positive disease after prior systemic therapy. The FDA granted full approval for this use in 2024 based on the MIRASOL trial (FDA, 2024).
Immunotherapy is an active area of research, but its role in ovarian cancer is still evolving. It has not changed routine care the way it has in some other cancers, although some biomarker defined groups may benefit and clinical trials remain important (Kumar et al., 2024; NCI, 2025).
What is the outlook for people with Ovarian Cancer?
The outlook for ovarian cancer depends on the stage at diagnosis, cancer subtype, grade, how much disease can be removed at surgery, response to chemotherapy, and tumor biology such as BRCA status. No single survival number tells the full story for an individual person, and newer treatments mean some people do better than older statistics suggest (American Cancer Society, 2025; NCI, 2025).
For invasive epithelial ovarian cancer in the SEER data used by the American Cancer Society, the 5 year relative survival is about 92 percent when disease is localized, 71 percent when regional, and 32 percent when distant, with 51 percent across all stages combined (American Cancer Society, 2025).
There are also differences by subtype. Stromal and germ cell tumors often have a better outlook than invasive epithelial cancers. Some tumors linked to BRCA changes may respond especially well to platinum drugs and PARP inhibitors (American Cancer Society, 2025; NCI, 2025).
If you are reading survival statistics after a new diagnosis, it is normal to feel frightened. But online averages do not know your exact stage, your pathology, your response to treatment, or what newer therapies may mean in your case. Your own oncologist can place those numbers in context far better than a search result can.
Living with Ovarian Cancer: Practical Tips for Patients and Families
Living with ovarian cancer often means managing both the disease and the uncertainty that comes with it. Good supportive care includes symptom control, nutrition support, physical activity as tolerated, mental health care, follow up visits, and honest conversations about what matters most to the patient right now (American Cancer Society, 2025; NICE, 2025).
After treatment, many people still deal with fatigue, bowel changes, neuropathy, surgical menopause, sleep problems, fear of recurrence, and changes in relationships or intimacy. These are real medical and emotional issues, not small side notes. Bring them up.
Helpful day to day steps include:
Keep a simple symptom diary
Eat small, regular meals if fullness or nausea makes large meals hard
Ask early about pain relief, constipation treatment, nausea control, and menopause support when needed
Stay as physically active as you safely can, even if activity starts with short walks
Avoid tobacco, limit alcohol, and work toward a healthy eating pattern over time
Accept support from family, counselors, support groups, or palliative care if that feels right
The American Cancer Society advises cancer survivors to avoid tobacco, stay physically active, maintain a healthy weight when possible, and follow a healthy eating pattern rich in fruits, vegetables, and whole grains. These steps do not replace treatment, but they support overall recovery and long term health (American Cancer Society, 2025).
Caregivers need support too. Clear updates, written questions for appointments, and a second set of ears during consultations can reduce stress for everyone.
When should you talk to a cancer specialist about Ovarian Cancer?
You should speak with a cancer specialist promptly if you have persistent bloating, pelvic or abdominal pain, feeling full quickly, urinary urgency, a pelvic mass, unexplained fluid in the abdomen, or abnormal test results that raise concern for ovarian cancer. Specialist review is also important when there is a strong family history of ovarian, breast, colon, or endometrial cancer (NICE, 2025; NCI, 2024).
A gynecologic oncologist is often the best specialist for suspected ovarian cancer because surgery, staging, pathology review, and treatment sequencing are complex. Getting the first plan right can affect outcomes.
You may also want specialist input if:
You have been told you have an ovarian cyst or pelvic mass and the next step is unclear
Your CA125 is raised and symptoms are continuing
You want a second opinion on surgery, chemotherapy, or maintenance therapy
You want genetic testing or advice for family members
The cancer has returned and you need to understand new options
For some patients, an online consultation can make expert care easier to access, especially when travel is difficult or treatment choices are complicated. The most useful consultations are the ones where pathology, scan reports, prior treatment details, and your own questions are ready beforehand.
Frequently Asked Questions about Ovarian Cancer
Can ovarian cancer be found early?
Yes, sometimes, but early detection is difficult because symptoms can be vague and there is no proven routine screening test for average risk women. Early stage disease is more treatable, which is why new persistent symptoms should not be ignored (NCI, 2025).
Is bloating always a sign of ovarian cancer?
No. Bloating is far more often caused by non cancer conditions. What matters is bloating that is new, frequent, persistent, and happening with other concerning symptoms like pelvic pain or feeling full quickly (American Cancer Society, 2025; NICE, 2025).
Does a high CA125 mean I have ovarian cancer?
No. CA125 can be raised in ovarian cancer, but it can also be high in endometriosis, pregnancy, liver disease, and other non cancer problems. It is a useful clue, not a diagnosis by itself (NCI, 2025; NICE, 2025).
Is ovarian cancer hereditary?
Sometimes. A meaningful minority of cases are linked to inherited syndromes such as BRCA1, BRCA2, or Lynch syndrome. That is why genetic counseling and testing are often discussed after diagnosis, especially if there is a family history of related cancers (NCI, 2024; NCI, 2025).
Can ovarian cancer come back after treatment?
Yes. Recurrence can happen even after a good initial response, especially in advanced stage epithelial ovarian cancer. If that happens, treatment choices depend on how long the cancer stayed under control, prior medicines used, symptoms, and tumor markers such as BRCA or folate receptor alpha status (NCI, 2025; FDA, 2024).
Should I get a second opinion?
A second opinion is very reasonable, especially before major surgery, when choosing maintenance therapy, or if the disease returns. It can confirm the plan, reveal other options, and give patients more confidence in the path ahead.
References
Need support with diagnosis, treatment planning, or a second opinion? Connect with our cancer care experts today.
Book Consultation